File photo: The Bristol Myers Squibb Research and Development Center in Cambridge Crossing in Cambridge, Massachusetts, December 27, 2023.
Adam Glanzman | Bloomberg | Getty Images
Bristol Myers Squibb On Thursday, he beat estimates of the first quarter and increased his advice on income and profits for the year, as the drug manufacturer reduces costs.
The company now plans that 2025 revenues are between $ 45.8 billion and $ 46.8 billion, against a previous perspective of approximately $ 45.5 billion. Bristol MYERS also provides for a profit adjusted in year full of $ 6.70 to $ 7 per share, which is compared to its previous forecasts from $ 6.5 to $ 6.85 per share.
In particular, the company said that its directive revisions included the estimated impact of current prices on American products shipped to China. But they do not take into account any of President Donald Trump’s planned tariffs on imported pharmaceuticals in the United States, Bristol Myers said.
China is a critical market for Bristol Myers Squibb. The company previously described its “China 2030 strategy”, which is a plan to bring more of its drugs to the nation to meet unmet medical needs in areas like gastric cancer and include more Chinese patients in clinical trials.
The company said that the increase in prospects reflects the strength of the company’s more recent drugs of the company, and sales of the first quarter more awaited compared to its portfolio inherited from older drugs.
The results arise while Bristol Myers Squibb moves to reduce $ 2 billion in spending by the end of 2027, which represents $ 1.5 billion in cost reductions provided by the end of this year.
This also occurs just a few days after the recently approved schizophrenia medication by Bristol Myers Squibb, Cobenfy, disappointed with a large clinical trial, which has led certain Wall Street analysts to considerably reduce their sales forecasts of several billion dollars for treatment.
BANCE SUR COBENFY company and other so -called growth portfolio drugs to compensate for the most sold income loss that should lose exclusivity on the market, including its immunotherapy ulot therapy against immunotherapy against successful cancer.
Here is what Bristol Myers reported for the first quarter compared to what Wall Street was waiting, on the basis of a survey of LSEG analysts:
- Profit by action: $ 1.80 adjusted vs $ 1.49 expected
- Income: $ 11.2 billion against $ 10.7 billion expected
Bristol Myers posted a net profit of 2.5 billion dollars, or $ 1.20 per share, for the first quarter. This is compared to a net loss of $ 11.9 billion, or a loss of $ 5.89 per share, for the annual period.
Excluding certain articles, he declared a profit adjusted per share of $ 1.80 for the quarter.
The income of the pharmaceutical giant fell 6% from the same period a year ago to 11.2 billion dollars.
Elishis reserved $ 3.57 billion in sales for the quarter, down 4% compared to the period of the previous year. This exceeds $ 3.34 billion to which analysts were waiting, according to the estimates compiled by Streetaccount.
The thinner blood, which Bristol Myers shares with Pfizer, should lose the exclusivity of the market by 2028.
Elilis sales could also take a hit in 2026, when a new price negotiated for the drug comes into force for certain drug patients after negotiations with the federal government. These discussions on prices are a key provision of the law on the reduction of inflation.
The second series of negotiations targets 15 additional drugs and will set new prices which will enter into force in 2028. This includes the drug Bristol Myers Pomalyst, which is used to treat blood cancer called multiple myelome and different cancer that develops in living people.
Pomalyst reported $ 658 million for the period, down 24% compared to the annual period. Revlimid, a drug used to treat adults with multiple myeloma, made $ 936 million in sales for the first quarter, down 44% compared to the same period a year ago.
Revenues from the so-called company growth portfolio were $ 5.56 billion for the first quarter, up 16% compared to the annual period.
Opdivo reported $ 2.27 billion in revenues for the first quarter, increasing by 9% compared to the annual period. This exceeds the estimate of analysts of $ 2.16 billion for the quarter, said Streetaccount.
Meanwhile, Cobenfy has reserved $ 27 million in sales for the first quarter.